

Curriculum Vitae

Personal information Ole Wichman

Work experience

Aug 2009 → today

Director of Immunization Unit, Robert Koch Institute (RKI), Berlin, Germany

-Management of the Immunization Unit at Robert Koch Institute. The unit is in charge of the surveillance and control of vaccine preventable diseases in Germany, of conducting epidemiological research on the impact and effectiveness of vaccines after their licensure, and of monitoring vaccine uptake and acceptance in the population. The unit also hosts the executive secretariat of the German National Immunization Technical Advisory Group (STIKO) and is thereby involved in the development of national vaccination recommendations and national immunization policy-making.

-Supervisor / principle investigator for various epidemiological and health economic research projects on vaccine-preventable diseases (e.g. COVID-19, measles, HPV, rotavirus, herpes zoster, influenza) to support decision-making related to vaccine introduction and implementation of immunization strategies.

-National contact point for vaccine-preventable diseases and the national immunization program in Germany (for communications with international health authorities such as WHO or ECDC).

Nov 2006 → Jan 2017

Medical Officer, World Health Organization, Geneva, Switzerland

3-months short-term assignment (unpaid leave at Robert Koch Institute). Work within the Department of Immunization, Vaccines and Biologicals (IVB) as part of the Policy and Strategies Group of the Expanded Programme on Immunization (EPI) Team. Main responsibilities:

-To conduct or coordinate scientific analyses, reviews and synthesis of evidence to inform the development of WHO policy and strategies related to immunization.

-To support the drafting of WHO recommendations and position papers on vaccines and immunization, based on the guidance provided by SAGE.

-To design and develop guidance materials and tools on vaccine-specific policies, strategies and evidence-based recommendations.

Jan 2008–July 2009

Medical Epidemiologist and Project Officer, International Vaccine Institute (IVI), Seoul, S-Korea

- Project officer for dengue field sites:
 - a) prospective school-based cohort study in Thailand;
 - b) prospective community-based cohort study in Cambodia.
- Socio-behavioural study on participation in a phase 2b randomized controlled trial in Thailand
- PRNT-studies on dengue antibody response and decay following natural infection
- Participation in dengue health economics studies:
 - a) cost-of-illness study in Cambodia,
 - b) development of a cost-effectiveness model in cooperation with US-CDC.

Education and training

2012

Habilitation

(title in German: "Privatdozent (PD)"; equivalent to "associate professor")
Charité University Medicine, Berlin

Academic teaching, scientific writing, supervision of young researchers

Title of postdoctoral / habilitation thesis: "Epidemiology, clinical manifestations and prevention of dengue in Southeast Asia and among European travellers"

Jan 2006 - Dec 2007

Fellow, German Field Epidemiology Training Programme (FETP)

- Participation in FETP and EPIET training modules in infectious disease epidemiology
- Conduct of a phylogenetic and case-control study on hepatitis E virus infection in Germany
- Conduct of a measles outbreak investigation and retrospective school cohort study to assess measles vaccine effectiveness in Germany
- International mission with Epicentre: Rift Valley Fever outbreak investigation and implementation of a malaria surveillance system in Ijara, Kenya.

2002–2003

Master in Clinical Tropical Medicine (M.C.T.M.)

Bangkok School of Tropical Medicine, Mahidol University, Bangkok, Thailand

Conducting clinical research in tropical countries, advanced tropical medicine, biostatistics.

Master thesis: "Risk factors and clinical features associated with severe dengue infection in adults and children during the 2001 epidemic in Chonburi, Thailand."

1994 - 2000

Medical degree (MD)

Additional information

Publications

Topic: Systematic Reviews on the effectiveness or safety of vaccines

1. Piechotta V, Siemens W, Thielemann I, Toews M, Koch J, Vygen-Bonnet S, Kothari K, Grummich K, Braun C, Kapp P, Labonté V, Wichmann O, Meerpohl JJ, Harder T. Safety and effectiveness of vaccines against COVID-19 in children aged 5-11 years: a systematic review and meta-analysis. *Lancet Child Adolesc Health*. 2023 Apr 18:S2352-4642(23)00078-0. doi: 10.1016/S2352-4642(23)00078-0.
2. Külper-Schiek W, Piechotta V, Pilic A, Batke M, Dreveton LS, Geurts B, Koch J, Köppe S, Treskova M, Vygen-Bonnet S, Waize M, Wichmann O, Harder T. Facing the Omicron variant-how well do vaccines protect against mild and severe COVID-19? Third interim analysis of a living systematic review. *Front Immunol*. 2022 Aug 24;13:940562.
3. Harder T, Külper-Schiek W, Reda S, Treskova-Schwarzbach M, Koch J, Vygen-Bonnet S, Wichmann O. Effectiveness of COVID-19 vaccines against SARS-CoV-2 infection with the Delta (B.1.617.2) variant: second interim results of a living systematic review and meta-analysis, 1 January to 25 August 2021. *Euro Surveill*. 2021 Oct;26(41):2100920.
4. Harder T, Koch J, Vygen-Bonnet S, Külper-Schiek W, Pilic A, Reda S, Scholz S, Wichmann O. Efficacy and effectiveness of COVID-19 vaccines against SARS-CoV-2 infection: interim results of a living systematic review, 1 January to 14 May 2021. *Euro Surveill*. 2021 Jul;26(28):2100563.
5. O Murchu E, Comber L, Jordan K, Hawkshaw S, Marshall L, O'Neill M, Ryan M, Teljeur C, Carnahan A, Pérez JJ, Robertson AH, Johansen K, Jonge J, Krause T, Nicolay N, Nohynek H, Pavlopoulou I, Pebody R, Penttinen P, Soler-Soneira M, Wichmann O, Harrington P. **Systematic review of the efficacy, effectiveness and safety of MF59® adjuvanted seasonal influenza vaccines for the prevention of laboratory-confirmed influenza in individuals ≥18 years of age.** *Rev Med Virol* 2022 Feb 10: e2329. doi: 10.1002/rmv.2329.
6. Jordan K, Murchu EO, Comber L, Hawkshaw S, Marshall L, O'Neill M, Teljeur C, Harrington P, Carnahan A, Pérez-Martín JJ, Robertson AH, Johansen K, Jonge J, Krause T, Nicolay N, Nohynek H, Pavlopoulou I, Pebody R, Penttinen P, Soler-Soneira M, Wichmann O, Ryan M. **Systematic review of the efficacy, effectiveness and safety of cell-based seasonal influenza vaccines for the prevention of laboratory-confirmed influenza in individuals ≥18 years of age.** *Rev Med Virol* 2022 Feb 8:e2332. doi: 10.1002/rmv.2332.
7. Comber L, O Murchu E, Jordan K, Hawkshaw S, Marshall L, O'Neill M, Teljeur C, Ryan M, Carnahan A, Pérez Martín JJ, Robertson AH, Johansen K, de Jonge J, Krause T, Nicolay N, Nohynek H, Pavlopoulou I, Pebody R, Penttinen P, Soler-Soneira M, Wichmann O, Harrington P. **Systematic review of the efficacy, effectiveness and safety of high-dose seasonal influenza vaccines for the prevention of laboratory-confirmed influenza in individuals ≥18 years of age.** *Rev Med Virol* 2022 Feb 4:e2330. doi: 10.1002/rmv.2330
8. O Murchu E, Comber L, Jordan K, Hawkshaw S, Marshall L, O'Neill M, Ryan M, Teljeur C, Carnahan A, Pérez JJ, Robertson AH, Johansen K, Jonge J, Krause T, Nicolay N, Nohynek H, Pavlopoulou I, Pebody R, Penttinen P, Soler-Soneira M, Wichmann O, Harrington P. **Systematic**

review of the efficacy, effectiveness and safety of recombinant haemagglutinin seasonal influenza vaccines for the prevention of laboratory-confirmed influenza in individuals ≥ 18 years of age. *Rev Med Virol* **2022** Feb 2:e2331. doi: 10.1002/rmv.2331.

9. Boender TS, Bartmeyer B, Coole L, [Wichmann O](#), Harder T. **Risk of Guillain-Barré syndrome after vaccination against human papillomavirus: a systematic review and meta-analysis, 1 January 2000 to 4 April 2020.** *Euro Surveill* **2022** Jan;27(4):2001619. doi: 10.2807/1560-7917.ES.2022.27.4.2001619.
10. Harder T, Külper-Schiek W, Reda S, Treskova-Schwarzbach M, Koch J, Vygen-Bonnet S, [Wichmann O](#). **Effectiveness of COVID-19 vaccines against SARS-CoV-2 infection with the Delta (B.1.617.2) variant: second interim results of a living systematic review and meta-analysis, 1 January to 25 August 2021.** *Euro Surveill* **2021** Oct;26(41):2100920. doi: 10.2807/1560-7917.ES.2021.26.41.2100920.
11. Harder T, Koch J, Vygen-Bonnet S, Külper-Schiek W, Pilic A, Reda S, Scholz S, [Wichmann O](#). **Efficacy and effectiveness of COVID-19 vaccines against SARS-CoV-2 infection: interim results of a living systematic review, 1 January to 14 May 2021.** *Euro Surveill* **2021** Jul;26(28):2100563. doi: 10.2807/1560-7917.ES.2021.26.28.2100563
12. Treskova M, Pozo-Martin F, Scholz S, Schönfeld V, [Wichmann O](#), Harder T. **Assessment of the Effects of Active Immunisation against Respiratory Syncytial Virus (RSV) using Decision-Analytic Models: A Systematic Review with a Focus on Vaccination Strategies, Modelling Methods and Input Data.** *Pharmacoeconomics* **2021** Mar;39(3):287-315. doi: 10.1007/s40273-020-00991-7.
13. Kling K, Harder T, Younger Z, Burchard G, Schmidt-Chanasit J, [Wichmann O](#). **Vaccination against Japanese encephalitis with IC51: systematic review on immunogenicity, duration of protection and safety.** *J Travel Med* **2020** Mar 13;27(2).
14. Sinzinger AX, Von Kries R, Siedler A, [Wichmann O](#), Harder T. **Non-specific effects of MMR vaccines on infectious disease related hospitalizations during the second year of life in high-income countries: a systematic review and meta-analysis.** *Hum Vaccin Immunother.* **2019** Oct 18:1-9.
15. Harder T, [Wichmann O](#), Klug SJ, van der Sande M, Wiese-Posselt M. **Efficacy, effectiveness and safety of vaccination against human papillomavirus in males: a systematic review.** *BMC Medicine* **2018**, Jul 18;16(1):110. doi: 10.1186/s12916-018-1098-3
16. Koch J, Harder T, von Kries R, [Wichmann O](#). **Risk of Intussusception After Rotavirus Vaccination.** *Deutsches Arzteblatt International* **2017**; 114(15):255-262
17. Harder T, Koch J, [Wichmann O](#), Hellenbrand W. **Predicted vs observed effectiveness of outer membrane vesicle (OMV) vaccines against meningococcal serogroup B disease: Systematic review.** *Journal of Infection* **2017**; 75(2):81-94.
18. Damm O, Ultsch B, Horn J, Mikolajczyk RT, Greiner W, [Wichmann O](#). **[Systematic review of models assessing the economic value of routine varicella and herpes zoster vaccination in high-income countries.](#)** *BMC Public Health* **2015** Jun 5;15:533.
19. Deléré Y, [Wichmann O](#), Klug SJ, van der Sande M, Terhardt M, Zepp F, Harder T. **The Efficacy and Duration of Vaccine Protection Against Human Papillomavirus: A Systematic Review and Meta-analysis.**

Deutsches Arzteblatt International **2014**; 111(35-36): 584-91.

20. Falkenhorst G, Remschmidt C, Harder T, Hummers-Pradier E, Wichmann O, Bogdan C. **Effectiveness of the 23-Valent Pneumococcal Polysaccharide Vaccine (PPV23) against Pneumococcal Disease in the Elderly: Systematic Review and Meta-Analysis.** *PLoS One* **2017**; 12(1).
21. Remschmidt C, Harder T, Wichmann O, Bogdan C, Falkenhorst G. **Effectiveness, immunogenicity and safety of 23-valent pneumococcal polysaccharide vaccine revaccinations in the elderly: a systematic review.** *BMC Infectious Diseases* **2016**; 16(1):711.
22. Remschmidt C, Wichmann O, Harder T. **Vaccines for the prevention of seasonal influenza in patients with diabetes: systematic review and meta-analysis.** *BMC Medicine* **2015** Mar 17; 13:53.
23. Remschmidt C, Wichmann O, Harder T. **Frequency and impact of confounding by indication and healthy vaccinee bias in observational studies assessing influenza vaccine effectiveness: a systematic review.** *BMC Infectious Diseases* **2015**; 15:429
24. Remschmidt C, Wichmann O, Harder T. **Influenza vaccination in patients with end-stage renal disease: Systematic review and assessment of quality of evidence related to vaccine efficacy, effectiveness and safety.** *BMC Medicine* **2014**, Dec 19; 12:244.
25. Remschmidt C, Wichmann O, Harder T. **Influenza vaccination in HIV-infected individuals: Systematic review and assessment of quality of evidence related to vaccine efficacy, effectiveness and safety.** *Vaccine* **2014**, 32(43):5585-92.
26. Remschmidt C, Wichmann O, Harder T. **Methodological quality of systematic reviews on influenza vaccination.** *Vaccine* **2014**; 32(15): 1678-84.
27. Beatty M, Beutels P, Meltzer M, Shepard, D, Hombach J, Hutubessy R, Dessis D, Coudeville L, Dervaux B, Wichmann O, Margolis H, Kuritsky J. **Health Economics of Dengue: A Systematic Literature Review and Expert Panel's Assessment.** *American Journal of Tropical Medicine and Hygiene* **2011**; 84: 473-88.

Topic: Immunization policy-making, collaboration of NITAGs

28. Mosina L, Külper-Schiek W, Jacques-Carroll L, Earnshaw A, Harder T, Martínón-Torres F, Wilder-Smith A, Wichmann O, Datta SS. **Supporting National Immunization Technical Advisory Groups in the WHO European Region in developing national COVID-19 vaccination recommendations through online communication platform.** *Vaccine* **2021** Oct 29;39(45):6595-6600. doi: 10.1016/j.vaccine.2021.09.034.
29. Jo CL, Burchett H, Bastías M, Campbell P, Gamage D, Henaff L, Kagina B, Lunny C, Marti M, Mulojiwa R, Pieper D, Thomas J, Tunis MC, Wichmann O, Younger Z, Harder T. **Using existing systematic reviews for developing vaccination recommendations: Results of an international expert workshop.** *Vaccine* **2021** May 27;39(23):3103-3110. doi: 10.1016/j.vaccine.2021.04.045.
30. MacDonald NE, Duclos P, Wichmann O, Henaff L, Harnden A, Alshammary A, Tijerino RA, Hall M, Sacarlal J, Singh RR. **Moving forward on strengthening and sustaining National Immunization**

Technical Advisory Groups (NITAGs) globally: Recommendations from the 2nd global NITAG network meeting. *Vaccine* **2017**; 35(50): 6925-6930.

31. Perronne C, Adjagba A, Duclos P, Floret D, Houweling H, Le Goaster C, Lévy-Bühl D, Meyer F, Senouci K, Wichmann O. **Implementing efficient and sustainable collaboration between National Immunization Technical Advisory Groups: Report on the 3rd International Technical Meeting, Paris, France, 8-9 December 2014.** *Vaccine* **2016**; 34(11): 1325-30.
32. Ultsch B, Damm O, Beutels P, Bilcke J, Brüggengjürgen B, Gerber-Grote A, Greiner W, Hanquet G, Hutubessy R, Jit M, Knol M, von Kries R, Kuhlmann A, Levy-Bruhl D, Perleth M, Postma M, Salo H, Siebert U, Wasem J, Wichmann O. **Methods for Health Economic Evaluation of Vaccines and Immunization Decision Frameworks: A Consensus Framework from a European Vaccine Economics Community.** *Pharmacoeconomics* **2016**; 34(3): 227-44
33. Pfeleiderer M, Wichmann O. **[From the licensure of vaccines to the recommendation of the Standing Committee on Vaccination in Germany: criteria for the assessment of benefits and risks].** *Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz* **2015**; 58(3): 263-73.
34. Takla A, Wichmann O, Carrillo-Santistevé P, Cotter S, Levy-Bruhl D, Paradowska-Stankiewicz I, Valentiner-Branth P, D'Ancona F; VENICE III NITAG Survey Group. **Characteristics and practices of National Immunisation Technical Advisory Groups in Europe and potential for collaboration, April 2014.** *Eurosurveillance* **2015** Mar 5;20(9).
35. Galanakis E, D'Ancona F, Jansen A, Lopalco PL; VENICE (Vaccine European New Integrated Collaboration Effort) National Gatekeepers, Contact Points. **The issue of mandatory vaccination for healthcare workers in Europe.** *Expert Review Vaccines* **2014**; 13(2): 277-83.
36. Nohynek H, Wichmann O, D'Ancona F; VENICE National Gatekeepers. **National Advisory Groups and their role in immunization policy-making processes in European countries.** *Clinical Microbiology & Infection* **2013**; 19(12): 1096-105.
37. Matysiak-Klose D, Ahmed F, Duclos P, Falck-Ytter Y, Forland F, Houweling H, Kramarz P, Langley JM, Mertens T, Schünemann H, Senouci K, Temte J, Wichmann O. **Report on the 1st international workshop on procedures for the development of evidence-based vaccination recommendations, Berlin, Germany, 22-23 November 2010.** *Vaccine* **2012** Mar 23; 30(14): 2399-404.

Topic: vaccine uptake monitoring, vaccine hesitancy

38. Neufeind J, Betsch C, Zylka-Menhorn V, Wichmann O. **Determinants of physician attitudes towards the new selective measles vaccine mandate in Germany.** *BMC Public Health* **2021** Mar 22;21(1):566. doi: 10.1186/s12889-021-10563-9
39. Neufeind J, Betsch C, Habersaat KB, Eckardt M, Schmid P, Wichmann O. **Barriers and drivers to adult vaccination among family physicians - Insights for tailoring the immunization program in Germany.** *Vaccine* **2020** Jun 2;38(27):4252-4262. doi: 10.1016/j.vaccine.2020.04.052.
40. Böhm S, Röbl-Mathieu M, Scheele B, Wojcinski M, Wichmann O, Hellenbrand W. **Influenza and pertussis vaccination during**

pregnancy - attitudes, practices and barriers in gynaecological practices in Germany. *BMC Health Serv Res* **2019**; 19(1): 616.

41. Betsch C, Rossmann C, Pletz MW, Vollmar HC, Freytag A, Wichmann O, Hanke R, Hanke W, Heinemeier D, Schmid P, Eitze S, Weber W, Reinhardt A, K pke NK, Forstner C, Fleischmann-Struzek C, Mikolajetz A, R mhild J, Neufeind J, Rieck T, Suchecka K, Reinhart K. **Increasing influenza and pneumococcal vaccine uptake in the elderly: study protocol for the multi-methods prospective intervention study Vaccination60.** *BMC Public Health* **2018** Jul 16;18(1):885.
42. Betsch C, B deker B, Schmid P, Wichmann O. **How baby's first shot determines the development of maternal attitudes towards vaccination.** *Vaccine* **2018**; 17; 36(21): 3018-3026.
43. Boes L, Boedeker B, Schmich P, Wetzstein M, Wichmann O, Remschmidt C. **Factors associated with parental acceptance of seasonal influenza vaccination for their children - A telephone survey in the adult population in Germany.** *Vaccine* **2017**; 35(30):3789-3796.
44. B deker B, Remschmidt C, Schmich P, Wichmann O. **Why are older adults and individuals with underlying chronic diseases in Germany not vaccinated against flu? A population-based study.** *BMC Public Health* **2015**, 15:618.
45. B deker B, Betsch C, Wichmann O. **Skewed risk perceptions in pregnant women: the case of influenza vaccination.** *BMC Public Health* **2015**; 16(1):1308.
46. B deker B, Remschmidt C, M ters S, Wichmann O. **[Influenza, tetanus, and pertussis vaccination coverage among adults in Germany].** *Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz* **2015**; 58(2): 174-81.
47. Rieck T, Feig M, Deler  Y, Wichmann O. **Utilization of administrative data to assess the association of an adolescent health check-up with human papillomavirus vaccine uptake in Germany.** *Vaccine* **2014**, 32(43):5564-9.
48. Rieck T, Feig M, Eckmanns T, Benzler J, Siedler A, Wichmann O. **Vaccination coverage among children in Germany estimated by analysis of health insurance claims data.** *Human Vaccines & Immunotherapeutics* **2014**; 10(2): 476-84.
49. B deker B, Walter D, Reiter S, Wichmann O. **Cross-sectional study on factors associated with influenza vaccine uptake and pertussis vaccination status among pregnant women in Germany.** *Vaccine* **2014**; 32(33):4131-9.
50. Takla A, Wichmann O, Koch J, Terhardt M, Hellenbrand W. **Survey of pediatricians in Germany reveals important challenges for possible implementation of meningococcal B vaccination.** *Vaccine* **2014**, 32(48):6349-55.
51. Remschmidt C, Walter D, Schmich P, Wetzstein M, Yvonne D, Wichmann O. **Knowledge, attitude, and uptake related to human papillomavirus vaccination among young women in Germany recruited via a social media site.** *Human Vaccines & Immunotherapeutics* **2014**, 10(9):2527-35.
52. Walter D, Atzpodien K, Pins C, Wichmann O, Reiter S. **Factors influencing the uptake of vaccines by adolescents with migration background : A qualitative study of adolescents, mothers, and**

physicians. *Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz* **2013**; 56(10):1368-75. [Article in German].

53. Böhmer MM, Hellenbrand W, Matysiak-Klose D, Heining U, Müters S, Wichmann O. **Pertussis vaccination coverage among adults in Germany.** *Deutsche Medizinische Wochenschrift* **2013**; 138(28-29):1451-7. [Article in German].
54. Stöcker P, Dehnert M, Schuster M, Wichmann O, Deleré Y. **Human papillomavirus vaccine uptake, knowledge and attitude among 10th grade students in Berlin, Germany, 2010.** *Human Vaccines & Immunotherapeutics* **2013**; 9(1):74-82.
55. Böhmer, M.M., Walter, D., Ehrhardt, J., Reiter, S., Krause, G., Wichmann, O. **Seasonal and Pandemic Influenza Vaccination: Coverage and Attitude among Private Physicians in Germany.** *Das Gesundheitswesen* **2013**, 76(1): 44-7. [Article in German].
56. Böhmer MM, Walter D, Falkenhorst G, Müters S, Krause G, Wichmann O. **Barriers to pandemic influenza vaccination and uptake of seasonal influenza vaccine in the post-pandemic season in Germany.** *BMC Public Health* **2012**; 12:938.
57. Walter D, Bohmer M, Reiter S, Krause G, Wichmann O. **Risk perception and information-seeking behaviour during the 2009/10 influenza A(H1N1)pdm09 pandemic in Germany.** *Euro Surveillance* **2012** Mar 29; 17(13). pii: 20131
58. Böhmer MM, Walter D, Krause G, Müters S, Gösswald A, Wichmann O. **Determinants of tetanus and seasonal influenza vaccine uptake in adults living in Germany.** *Human Vaccines* **2011**; 7 (12): 1317-25.
59. Böhmer MM, Walter D, Müters S, Krause G, Wichmann O. **Seasonal influenza vaccine uptake in Germany 2007/08 and 2008/09: Results from a national Health Update Survey.** *Vaccine* **2011**; 29(27):4492-8.
60. Walter D, Böhmer MM, Heiden MA, Reiter S, Krause G, Wichmann O. **Monitoring pandemic influenza A(H1N1) vaccination coverage in Germany 2009/10 - Results from thirteen consecutive cross-sectional surveys.** *Vaccine* **2011**, 29: 4008-12.

Topic: COVID-19

61. Treskova-Schwarzbach M, Haas L, Reda S, Pilic A, Borodova A, Karimi K, Koch J, Nygren T, Scholz S, Schönfeld V, Vygen-Bonnet S, Wichmann O, Harder T. **Pre-existing health conditions and severe COVID-19 outcomes: an umbrella review approach and meta-analysis of global evidence.** *BMC Med.* **2021** Aug 27;19(1):212. doi: 10.1186/s12916-021-02058-6.
62. Stoliaroff-Pepin A, Peine C, Herath T, Lachmann J, Perriat D, Dörre A, Nitsche A, Michel J, Grossegessle M, Hofmann N, Rinner T, Kohl C, Brinkmann A, Meyer T, Dorner BG, Stern D, Treindl F, Hein S, Werel L, Hildt E, Gläser S, Schühlen H, Isner C, Peric A, Ghouzi A, Reichardt A, Janneck M, Lock G, Schaade L, Wichmann O, Harder T. **Effectiveness of vaccines in preventing hospitalization due to COVID-19: A multicenter hospital-based case-control study, Germany, June 2021 to January 2022.** *Vaccine.* 2023 Jan 9;41(2):290-293.
63. Stoliaroff-Pepin A, Peine C, Herath T, Lachmann J, Hellenbrand W, Perriat D, Dörre A, Nitsche A, Michel J, Grossegessle M, Hofmann N, Rinner T, Kohl C, Brinkmann A, Meyer T, Stern D, Treindl F, Dorner BG, Hein S, Werel L, Hildt E, Gläser S, Schühlen H, Isner C, Peric A, Ghouzi A, Reichardt A, Janneck M, Lock G, Huster D, Grünwald T,

Topic: Measles / mumps

64. Friedrich N, Poethko-Müller C, Kuhnert R, Matysiak-Klose D, Koch J, Wichmann O, Santibanez S, Mankertz A. **Seroprevalence of Measles-, Mumps-, and Rubella-specific antibodies in the German adult population - cross-sectional analysis of the German Health Interview and Examination Survey for Adults (DEGS1).** *Lancet Reg Health Eur.* **2021** Jun 5;7:100128. doi: 10.1016/j.lanepe.2021.100128.
65. Takla A, Wichmann O, Rieck T, Matysiak-Klose D. **Review of surveillance and insurance data towards measles elimination in Germany.** *Bulletin of the World Health Organization* **2014**, 92(10):742-9.
66. Takla A, Böhmer MM, Klinc C, Kurz N, Schaffer A, Stich H, Stöcker P, Wichmann O, Koch J. **Outbreak-related mumps vaccine effectiveness among a cohort of children and of young adults in Germany 2011.** *Human Vaccines & Immunotherapeutics* **2014**; 10(1):140-5.
67. Takla A, Wichmann O, Klinc C, Hautmann W, Rieck T, Koch J. **Mumps epidemiology in Germany 2007-11.** *EuroSurveillance* **2013**; 18(33): 20557.
68. Lassen SG, Schuster M, Stemmler M, Steinmüller A, Matysiak-Klose D, Mankertz A, Santibanez S, Wichmann O, Falkenhorst G. **Measles outbreak spreading from the community to an anthroposophic school, Berlin, 2011.** *Epidemiology & Infection* **2014**, 142(4):789-96
69. Wichmann O¹, Ultsch B. **Effectiveness, population-level effects, and health economics of measles and rubella vaccination.** *Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz.* 2013 Sep;56(9):1260-9
70. Bonacic Marinovic AA, Swaan C, Wichmann O, van Steenberghe J, Kretzschmar M. **Effectiveness and Timing of Vaccination during School Measles Outbreaks.** *Emerging Infectious Disease* **2012**, 18(9): 1405-13.
71. Takla A, Barth A, Siedler A, Stöcker P, Wichmann O, Deleré Y. **Measles outbreak in an asylum-seekers' shelter in Germany: comparison of the implemented with a hypothetical containment strategy.** *Epidemiology & Infection* **2012**; 140(9):1589-98.
72. Siedler A, Mankertz A, Ahlemeyer G, Feil F, Hornig A, Scharkus S, Kirchner M, Beyrer K, Dreesman J, Marcic A, Reiter S, Matysiak-Klose D, Santibanez S, Krause G, Wichmann O. **Closer to the goal - efforts in measles elimination in Germany 2010.** *Journal of Infectious Diseases* **2011**, 204 (Suppl. 1), S373-380.
73. van Boven M, Kretzschmar M, Wallinga J, O'Neill PD, Wichmann O, Hahné S. **Estimation of measles vaccine efficacy and critical vaccination coverage in a highly vaccinated population.** *Journal of the Royal Society Interface* **2010**, 7:1537-1544.
74. Wichmann O, Siedler A, Hellenbrand W, Sagebiel D, Santibanez S, Mankertz A, Vogt G, van Treeck U, Krause G. **Further efforts needed to achieve measles elimination in Germany - Results of an outbreak investigation.** *Bulletin of the World Health Organization* **2009**, 87:108-15.

75. Wichmann O, Hellenbrand W, Sagebiel D, Santibanez S, Ahlemeyer A, Vogt G, Siedler A, van Treeck U. **Large measles outbreak at a German public school, 2006.** *Pediatric Infectious Disease Journal* **2007**, 26: 782-6.
76. van Treeck U, Wichmann O. **Measles outbreak in Germany: update.** *Eurosurveillance weekly* **2006** Apr 13; 11(4): E060413.1

Topic: Rotavirus

77. Weidemann F, Dehnert M, Koch J, Wichmann O, Höhle M. **Modelling the epidemiological impact of rotavirus vaccination in Germany – A Bayesian approach.** *Vaccine* **2014**, 32(40):5250-7.
78. Weidemann F, Dehnert M, Koch J, Wichmann O, Höhle M. **Bayesian parameter inference for dynamic infectious disease modelling: rotavirus in Germany.** *Statistics in Medicine* **2014**; 33(9): 1580-99.
79. Aidelburger P, Grabein K, Böhm K, Dietl M, Wasem J, Koch J, Ultsch B, Weidemann F, Wichmann O. **Cost-effectiveness of childhood rotavirus vaccination in Germany.** *Vaccine* **2014**; 32(17): 1964-74.
80. Koch J, Wiese-Posselt M, Remschmidt C, Wichmann O, Bertelsmann H, Garbe E, Hengel H, Meerpohl JJ, Mas Marques A, Oppermann H. **Background paper to the recommendation for routine rotavirus vaccination of infants in Germany.** *Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz* **2013**; 56(7): 957-84.
81. Adlhoch C, Hoehne M, Littmann M, Marques AM, Lerche A, Dehnert M, Eckmanns T, Wichmann O, Koch J. **Rotavirus vaccine effectiveness and case-control study on risk factors for breakthrough infections in Germany, 2010-2011.** *Pediatric Infectious Disease Journal* **2013**; 32(2): e82-9.
82. Dudareva-Vizule S, Koch J, An der Heiden M, Oberle D, Keller-Stanislawski B, Wichmann O. **Impact of rotavirus vaccination in regions with low and moderate vaccine uptake in Germany.** *Human Vaccines & Immunotherapeutics* **2012**; 8(10): 1407-15.

Topic: Human Papillomavirus (HPV)

83. Loenenbach A, Pawlita M, Waterboer T, Harder T, Poethko-Müller C, Thamm M, Lachmann R, Deleré Y, Wichmann O, Wiese-Posselt M. **Seroprevalence of mucosal and cutaneous human papillomavirus (HPV) types among children and adolescents in the general population in Germany.** *BMC Infect Dis* **2022** Jan 10;22(1):44. doi: 10.1186/s12879-022-07028-8.
84. Loenenbach AD, Poethko-Müller C, Pawlita M, Thamm M, Harder T, Waterboer T, Schröter J, Deleré Y, Wichmann O, Wiese-Posselt M. **Mucosal and cutaneous Human Papillomavirus seroprevalence among adults in the prevaccine era in Germany - Results from a nationwide population-based survey.** *Int J Infect Dis* **2019** Jun;83:3-11.
85. Takla A, Wiese-Posselt M, Harder T, Meerpohl JJ, Röbl-Mathieu M, Terhardt M, van der Sande M, Wichmann O, Zepp F, Klug SJ. **Background paper for the recommendation of HPV vaccination for boys in Germany.** *Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz* **2018** Sep;61(9):1170-1186.
86. Damm O, Horn J, Mikolajczyk RT, Kretzschmar MEE, Kaufmann AM,

- Deleré Y, Ultsch B, Wichmann O, Krämer A, Greiner W. **Cost-effectiveness of human papillomavirus vaccination in Germany. Cost Effectiveness and Resource Allocation** **2017**; 15:18.
87. Deleré Y, Renschmidt C, Leuschner J, Schuster M, Fesenfeld M, Schneider A, Wichmann O, Kaufmann AM. **Human Papillomavirus prevalence and probable first effects of vaccination in 20 to 25 year-old women in Germany: a population-based cross-sectional study via home-based self-sampling.** *BMC Infectious Diseases* **2014**; 14:87.
88. Deleré Y, Böhmer MM, Walter D, Wichmann O. **HPV vaccination coverage among women aged 18-20 years in Germany three years after recommendation of HPV vaccination for adolescent girls.** *Human Vaccines & Immunotherapeutics* **2013**, 9(8):1706-11
89. Horn J, Damm O, Kretzschmar MEE, Deleré Y, Wichmann O, Kaufmann AM, Garbe E, Krämer A, Greiner W, Mikolajczyk RT. **Estimating the long-term effects of HPV vaccination in Germany.** *Vaccine* **2013**, 1(19): 2372-80.
90. Renschmidt C, Kaufmann AM, Hagemann I, Vartazarova E, Wichmann O, Deleré Y. **Risk factors for cervical human papillomavirus infection and high-grade intraepithelial lesion in women aged 20 to 31 years in Germany.** *International Journal of Gynecological Cancer* **2013**; 23(3):519-26.

Topic: Varicella zoster virus

91. Horn J, Damm O, Greiner W, Hengel H, Kretzschmar ME, Siedler A, Ultsch B, Weidemann F, Wichmann O, Karch A, Mikolajczyk RT. **Influence of demographic changes on the impact of vaccination against varicella and herpes zoster in Germany - a mathematical modelling study.** *BMC Medicine* **2018**; 16(1):3.
92. Wiese-Posselt M, Siedler A, Mankertz A, Sauerbrei A, Hengel H, Wichmann O, Poethko-Müller C. **Varicella-zoster virus seroprevalence in children and adolescents in the pre-varicella vaccine era, Germany.** *BMC Infectious Diseases* **2017**; 17(1):356.
93. Rieck T, Feig M, An der Heiden M, Siedler A, Wichmann O. **Assessing varicella vaccine effectiveness and its influencing factors using health insurance claims data, Germany, 2006 to 2015.** *Euro Surveillance* **2017**; 22(17).
94. Horn J, Karch A, Damm O, Kretzschmar ME, Siedler A, Ultsch B, Weidemann F, Wichmann O, Hengel H, Greiner W, Mikolajczyk RT. **Current and future effects of varicella and herpes zoster vaccination in Germany – insights from a mathematical model in a country with universal varicella vaccination.** *Human Vaccines & Immunotherapeutics* **2016**, 12(7):1766-76.
95. Ultsch B, Weidemann F, Reinhold T, Siedler A, Krause G, Wichmann O. **Health economic evaluation of vaccination strategies for the prevention of herpes zoster and postherpetic neuralgia in Germany.** *BMC Health Service Research* **2013**; 13(1): 359.
96. Ultsch B, Köster I, Reinhold T, Siedler A, Krause G, Icks A, Schubert I, Wichmann O. **Epidemiology and cost of herpes zoster and postherpetic neuralgia in Germany.** *European Journal of Health Economics* **2012**; 14(6):1015-26.
97. Ultsch B, Siedler A, Rieck T, Reinhold T, Krause G, Wichmann O. **Herpes zoster in Germany: Quantifying the burden of disease.**

Topic: Meningococcal disease

98. Hellenbrand W, Claus H, Schink S, Marcus U, [Wichmann O](#), Vogel U. **Risk of Invasive Meningococcal Disease in Men Who Have Sex with Men: Lessons Learned from an Outbreak in Germany, 2012-2013.** *PLoS One* **2016**, Aug 3;11(8):e0160126.
99. Christensen H, Irving T, Koch J, Trotter CL, Ultsch B, Weidemann F, [Wichmann O](#), Hellenbrand W. **Epidemiological impact and cost-effectiveness of universal vaccination with Bexsero® to reduce meningococcal group B disease in Germany.** *Vaccine* **2016**, 34(29): 3412-9.
100. Koch J, Hellenbrand W, Schink S, [Wichmann O](#), Carganico A, Drewes J, Kruspe M, Suckau M, Claus H, Marcus U. **Evaluation of a temporary vaccination recommendation in response to an outbreak of invasive meningococcal serogroup C disease in men who have sex with men in Berlin, 2013-2014.** *Euro Surveillance* **2016**; 21(5).
101. Hellenbrand W, Koch J, Harder T, Bogdan C, Heininger U, Tenenbaum T, Terhardt M, Vogel U, [Wichmann O](#), von Kries R. **Background Paper for the update of meningococcal vaccination recommendations in Germany: use of the serogroup B vaccine in persons at increased risk for meningococcal disease.** *Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz* **2015**, 58: 1314-1343.
102. Marcus U, Vogel U, Schubert A, Claus H, Baetzing-Feigenbaum J, Hellenbrand W, [Wichmann O](#). **A cluster of invasive meningococcal disease in young men who have sex with men in Berlin, October 2012 to May 2013.** *Euro Surveillance* **2013**; 18(28).
103. Hellenbrand W, Elias J, [Wichmann O](#), Dehnert M, Frosch M, Vogel U. **Epidemiology of invasive meningococcal disease in Germany, 2002-2010, and impact of vaccination with meningococcal C conjugate vaccine.** *Journal of Infection* **2013**; 66(1): 48-56.

Topic: Influenza

104. Scholz SM, Weidemann F, Damm O, Ultsch B, Greiner W, [Wichmann O](#). **Cost-Effectiveness of Routine Childhood Vaccination Against Seasonal Influenza in Germany.** *Value Health* **2021** Jan;24(1):32-40. doi: 10.1016/j.jval.2020.05.022.
105. Neufeind J, Wenchel R, Boedeker B, Wicker S, Wichmann O. **Monitoring influenza vaccination coverage and acceptance among health-care workers in German hospitals - results from three seasons.** *Hum Vaccin Immunother* **2021** Mar 4;17(3):664-672. doi: 10.1080/21645515.2020.1801072.
106. Scholz S, Damm O, Schneider U, Ultsch B, [Wichmann O](#), Greiner W. **Epidemiology and cost of seasonal influenza in Germany - a claims data analysis.** *BMC Public Health* **2019** Aug 13;19(1):1090
107. Weidemann F, Remschmidt C, Buda S, Buchholz U, Ultsch B, [Wichmann O](#). **Is the impact of childhood influenza vaccination less than expected: a transmission modelling study.** *BMC Infectious Diseases* **2017**; 17(1):258
108. Remschmidt C, Rieck T, Bödeker B, [Wichmann O](#). **[Application of the](#)**

[screening method to monitor influenza vaccine effectiveness among the elderly in Germany.](#) *BMC Infectious Diseases* **2015** Mar 20;15: 137.

109. Grund S, [Wichmann O](#), Mertens T, Hengel H. **Concepts, effectiveness, and perspectives of pandemic and seasonal influenza vaccines.** Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz **2013**; 56(1):76-86. [Article in German].
110. Hellenbrand W, Jorgensen P, Schweiger B, Falkenhorst G, Nachtnebel M, Greutelaers B, Traeder C, [Wichmann O](#). **Prospective hospital-based case-control study to assess the effectiveness of pandemic influenza A(H1N1)pdm09 vaccination and risk factors for hospitalization in 2009- 2010 using matched hospital and test-negative controls.** *BMC Infectious Diseases* **2012**; 12(1):127.
111. Nachtnebel M, Greutelaers B, Falkenhorst G, Jorgensen P, Dehnert M, Schweiger B, Träder C, Buda S, Eckmanns T, [Wichmann O](#), Hellenbrand W. **Lessons from a one-year hospital-based surveillance of acute respiratory infections in Berlin- comparing case definitions to monitor influenza.** *BMC Public Health* **2012**; 12: 245.
112. Cramer J, Mac T, Hogan B, Stauga S, Eberhardt S, [Wichmann O](#), Mertens T, Burchard G. **Influenza A(H1N1)pdm09 antibodies after pandemic and trivalent seasonal influenza vaccination as well as natural infection in November 2010 in Hamburg, Germany.** *Euro Surveillance* **2012** Jan 12;17(2). pii: 20052.
113. Uphoff H, An der Heiden M, Schweiger B, Campe H, Beier D, Helmeke C, Littmann M, Haas W, Buda S, Faensen D, Feig M, Altmann D, [Wichmann O](#), Eckmanns T, Buchholz U. **Effectiveness of the AS03-adjuvanted vaccine against pandemic influenza virus A(H1N1) 2009--a comparison of two methods; Germany, 2009/10.** *PLoS One* **2011**; 6(7):e19932.
114. [Wichmann O](#), Stöcker P, Poggensee G, Altmann D, Walter D, Hellenbrand W, Krause G, Eckmanns T. **Pandemic influenza A(H1N1) 2009 breakthrough infections and estimates of vaccine effectiveness in Germany 2009-2010.** *Eurosurveillance* **2010**, 15 (18): 1-4.

Topic: Other publications related to vaccines or vaccine-preventable diseases

115. Nygren TM, Pilic A, Böhmer MM, Wagner-Wiening C, [Wichmann O](#), Harder T, Hellenbrand W. **Tick-Borne Encephalitis Risk Increases with Dog Ownership, Frequent Walks, and Gardening: A Case-Control Study in Germany 2018–2020.** *Microorganisms* **2022**, 10(4), 690
116. Storch J, Fleischmann-Struzek C, Rose N, Lehmann T, Mikolajetz A, Maddela S, Pletz MW, Forstner C, [Wichmann O](#), Neufeind J, Vogel M, Reinhart K, Vollmar HC, Freytag A; Vaccination 60+ Study Group. **The effect of influenza and pneumococcal vaccination in the elderly on health service utilisation and costs: a claims data-based cohort study.** *Eur J Health Econ.* **2022** Feb;23(1):67-80. doi: 10.1007/s10198-021-01343-8.
117. Takla A, Schönfeld V, Claus H, Krone M, An der Heiden M, Koch J, Vogel U, Wichmann O, Lâm TT. **Invasive Haemophilus influenzae Infections in Germany After the Introduction of Routine Childhood**

Immunization, 2001-2016. *Open Forum Infect Dis* **2020** Sep 18;7(10): ofaa444. doi: 10.1093/ofid/ofaa444.

118. Kreusch TM, Holding M, Hewson R, Harder T, Medlock JM, Hansford KM, Dowall S, Semper A, Brooks T, Walsh A, Russell K, Wichmann O. **A probable case of tick-borne encephalitis (TBE) acquired in England, July 2019.** *Euro Surveill.* **2019** Nov;24(47).
119. Hellenbrand W, Kreusch T, Böhmer MM, Wagner-Wiening C, Dobler G, Wichmann O, Altmann D. **Epidemiology of Tick-Borne Encephalitis (TBE) in Germany, 2001-2018.** *Pathogens* **2019** Mar 29;8(2).
120. Schielke A, Takla A, von Kries R, Wichmann O, Hellenbrand W. **Marked Under-Reporting of Pertussis Requiring Hospitalization in Infants as Estimated by Capture-Recapture Methodology, Germany, 2013-2015.** *Pediatric Infectious Disease Journal* **2018**; 37(2):119-125.
121. Falkenhorst G, Remschmidt C, Harder T, Wichmann O, Glodny S, Hummers-Pradier E, Ledig T, Bogdan C. **Background paper to the updated pneumococcal vaccination recommendation for older adults in Germany.** *Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz* **2016**; 59(12):1623-1657.
122. Anderson CL, Remschmidt C, Drobnitzky FP, Falkenhorst G, Zimmermann R, Wichmann O, Harder T. **Hepatitis B immune status in adolescents vaccinated during infancy: A retrospective cohort study from a pediatric practice in Germany.** *Human Vaccines & Immunotherapeutics* **2015** [Epub ahead of print]
123. Haller S, Dehnert M, Karagiannis I, Rieck T, Siffczyk C, Wichmann O, Poethko-Mueller C, Hellenbrand W. **Effectiveness of routine and booster pertussis vaccination in children and adolescents, federal state of Brandenburg, Germany, 2002-2012.** *Pediatric Infectious Disease Journal* **2015**; 34(5):513-9.

Topic: Dengue

124. Wichmann O, Vannice K, Asturias EJ, de Albuquerque Luna EJ, Longini I, Lopez AL, Smith PG, Tissera H, Yoon IK, Hombach J. **Live-attenuated tetravalent dengue vaccines: The needs and challenges of post-licensure evaluation of vaccine safety and effectiveness.** *Vaccine* **2017**; 35(42): 5535-5542.
125. Carod-Artal FJ, Wichmann O, Farrar J, Gascón J. **Neurological complications of dengue virus infection.** *Lancet Neurology* **2013**; 12(9): 906-19.
126. Douglas D, DeRoeck D, Mahoney RT, Wichmann O. **Will dengue vaccines be used in the public sector and if so, how? Results of an 8-country survey of policymakers and opinion leaders.** *PLOS Neglected Tropical Diseases* **2013**, Mar;7(3): e2127.
127. Vong S, Goyet S, Ngan C, Huy R, Ong S, Duong S, Wichmann O, Letson GW, Margolis HS, Buchy P. **Under-recognition and Reporting of Dengue in Cambodia: A capture – recapture analysis of the National Dengue Surveillance System.** *Epidemiology and Infection* **2012**; 140(3): 491-9.
128. Domingo C, Niedrig M, Gascón J, Palacios G, Reyes N, Malo MJ,

- Wichmann O, Ruiz J, Schultze D, Schunk M, Puente P, Vinner L, Van Esbroeck M, Schuffenecker I, Grandadam M, López-Vélez R, Tenorio A. **Molecular Surveillance Of Circulating Dengue Genotypes Through European Travelers.** *Journal of Travel Medicine* **2011**; 18: 183-190.
129. Wichmann O, Yoon IK, Vong S, Limkittikul K, Gibbons RV, Mammen PM, Ly S, Buchy P, Sirivichayakul C, Buathong R, Huy R, G. Letson GW, Sabchareon A. **Dengue in Thailand and Cambodia: An Assessment of the Degree of Underrecognized Disease Burden Based on Reported Cases.** *PLoS Neglected Tropical Diseases* **2011**; 5(3): e996.
 130. Amarasinghe A, Wichmann O, Margolis HS, Mahoney RT. **Potential dengue vaccine demand in disease endemic and non-endemic countries.** *Human Vaccines* **2010**, 9: 745- 753.
 131. Vong S, Khieu V, Glass O, Ly S, Ong S, Huy R, Ngan C, Wichmann O, Letson W, Margolis HM, Buchy P. **Dengue Incidence in Urban and Rural Cambodia: Results from Population-based Active Fever Surveillance, 2006-2008.** *PLoS Neglected Tropical Diseases* **2010**, Nov 30; 4(11): e903.
 132. Domingo C, de Ory F, Sanz JC, Reyes N, Gascón J, Wichmann O, Puente S, Schunk M, López-Vélez R, Ruiz J, Tenorio A. **Molecular and serological markers of acute dengue infection in naïve and flavivirus-vaccinated travellers.** *Diagnostic Microbiology and Infectious Disease* **2009**, 65: 42-8.
 133. Huy R, Wichmann O, Beatty M, Ngan C, Duong S, Margolis MS, Vong S. **Cost of dengue and other febrile illnesses to households in rural Cambodia: A prospective community-based case-control study.** *BMC Public Health* **2009**, 9(1):155.
 134. Wichmann O, Gascon J, Schunk M, Puente S, Siikamaki H, Gjørup H, Lopez-Velez R, Clerinx J, Peyerl-Hoffmann G, Sundøy A, Genton B, Kern P, Calleri G, de Górgolas M, Mühlberger N, Jelinek T. **Severe dengue infections in travelers: Risk factors and laboratory indicators.** *Journal of Infectious Diseases* **2007**, 195: 1089-1096.
 135. Wichmann O, Stark K, Shu PY, Niedrig M, Frank C, Huang JH, Jelinek T. **Clinical features and pitfalls in the laboratory diagnosis of dengue in travellers.** *BMC Infectious Diseases* **2006**, 6(1):120.
 136. Wichmann O, Lauschke A, Frank C, Shu PY, Niedrig M, Huang JH, Stark K, Jelinek T. **Dengue Antibody Prevalence in German Travelers.** *Emerging Infectious Diseases* **2005**, 11: 762-765.
 137. Wichmann O, Hongsiriwon S, Bowonwatanuwong C, Chotivanich K, Sukthana Y, Pukrittayakamee S. **Risk factors and clinical features associated with severe dengue infection in adults and children during the 2001-epidemic in Chonburi, Thailand.** *Tropical Medicine & International Health* **2004**; 9: 1022-1029.
 138. Wichmann O, Jelinek T. **Dengue in travellers - A review.** *Journal of Travel Medicine* **2004**; 11: 161-170.
 139. Wichmann O, Mühlberger N, Jelinek T. **Dengue – the underestimated risk in travellers.** In: World Health Organization, the South-East Asia and Western Pacific Region. *Dengue Bulletin – Vol. 27.* New Delhi: WHO; **2003**: 126-136.
 140. Wichmann O, Jelinek T. **TropNetEurop: Surveillance of dengue in Europe.** *Eurosurveillance Weekly* **2003**; 7 (32)

Topic: Hepatitis E

141. Lewis HC, Wichmann O, Duizer E. **Transmission routes and risk factors for autochthonous hepatitis E virus infection in Europe: a systematic review.** *Epidemiology and Infection* 2010, 138: 145-66.
142. Wichmann O, Schimanski S, Koch J, Kohler M, Rothe C, Plentz A, Jilg W, Stark K. **Phylogenetic and case-control study on hepatitis E virus infections in Germany.** *Journal of Infectious Diseases* 2008, 198: 1732-41.

Projects

- Epidemiological studies on the effects (mainly vaccine effectiveness and impact) of vaccination (e.g. case-control study on covid-19 vaccine effectiveness)
- Systematic Reviews on the efficacy, effectiveness and safety of vaccines
- Studies on the acceptance and barriers to vaccination or vaccine mandates

Memberships

- Member of the European Technical Advisory Group of Experts (ETAGE), WHO Regional Office for Europe, since 2017. Chair of ETAGE since December 2022.
- Member of the Steering Committee of the EU/EEA NITAG Collaboration (network of National Immunization Technical Advisory Groups in the EU), coordinated by ECDC, since 2019
- Member of the ECDC/EMA Joint Advisory Board on COVID-19 vaccine monitoring, since 2021
- Member of the "Committee on Immunization" of the Society of Virology (GfV) and the German Association for the Control of Virus Diseases (DVV), since 2015.

Other Relevant Information